Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page now shows revision v3.3.2 replacing v3.3.1; no study details or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedThe Publications section now includes clarifying statements that publications are voluntary input and are auto-filled from PubMed, and the page revision is labeled v3.3.1. The older language about PubMed-generated lists and study results wording has been removed, and 'To avoid being alerted by small changes, set an alert condition by clicking below.'SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding status notice, eliminating the lapse-in-funding banner from the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedThe update appears to be limited to minor UI/layout adjustments and an updated last update date; the core content (title, conditions, trial arms, eligibility criteria, and outcomes) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedMajor change: version bump to v3.2.0 and an important operating-status notice about government funding and NIH Clinical Center, directing users to official sources.SummaryDifference2%

- Check70 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.